Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / DSIP

DSIP

DSIP (delta sleep-inducing peptide): why its sleep effect was never confirmed, the July 2026 FDA advisory vote against it, and the safety unknowns.

Not approved anywhere · Evidence grade C · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes DSIP only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

2026 updateJuly 23 and 24, 2026: An FDA advisory committee voted on adding peptides to the list of substances pharmacies may compound. It narrowly recommended BPC-157 (for ulcerative colitis) and TB-500 (for wound healing), recommended MOTS-c 7 to 5 (for obesity and osteoporosis) and Semax (against the advice of FDA staff), and voted against DSIP.See every change in the 2026 tracker ›
Approved and studied uses
  • Not approvedSleepPromoted for sleep; a small trial found no clear benefit

DSIP (Delta sleep-inducing peptide, emideltide). Peptide.

CNot approved anywhere. Evidence grade C: limited, early or dated human data.

What is DSIP?

DSIP is a nine-amino-acid peptide first isolated from rabbit blood in 1977 and promoted for sleep. No gene or receptor for it has been identified, and a 2006 review called the idea that it is a sleep factor poorly documented.

Is DSIP FDA-approved?

Not approved in the United States, and FDA found no country where it is registered as a drug. FDA had listed it among bulk substances that may present significant safety risks in compounding. The nomination was later withdrawn, and in 2026 FDA moved it to a table of withdrawn nominations while keeping its safety notes. Leaving that list does not make it approved or eligible for compounding. In July 2026 an FDA advisory committee voted against adding it to the list of substances pharmacies may compound. It is the one peptide at that meeting the committee rejected, and it is not covered by the October 2026 HHS draft policy.

What does the evidence show for DSIP?

A double-blind trial in 16 people with chronic insomnia in 1992 found weak effects and no change in how people rated their sleep; the authors concluded it is not likely to be of major benefit. An uncontrolled 1984 series in alcohol and opiate withdrawal reported improvement but had no comparison group.

What are the known risks of DSIP?

FDA has no safety information for it and flags possible immune reactions and impurities. Headache was the only side effect noted in the 1984 series. Sport: no health authority has approved it, so it falls under the World Anti-Doping Code ban on unapproved substances, at all times.

How is DSIP measured?

Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.

Sources: FDA: emideltide (DSIP) briefing document, July 2026; FDA: bulk drug substances that may present significant safety risks; FDA: Pharmacy Compounding Advisory Committee, July 23 and 24, 2026; AJMC: FDA panel backs 6 peptides for compounding; Kovalzon and Strekalova, DSIP review (2006); Bes et al., DSIP in chronic insomnia (1992); Dick et al., DSIP in withdrawal (1984); WADA: 2026 Prohibited List. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.